You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBiperiden
Accession NumberDB00810  (APRD00725)
TypeSmall Molecule
GroupsApproved
DescriptionA muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. [PubChem]
Structure
Thumb
Synonyms
1-Bicyclo[2.2.1]hept-5-en-2-yl-1-phenyl-3-piperidin-1-yl-propan-1-ol
alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanol
alpha-Bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
Beperiden
Biperidene
Biperideno
Biperidenum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Akineton Tab 2mgtablet2 mgoralAbbott Laboratories, Limited1985-12-312007-07-31Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AkinetonAbbott
BilinoWinston
IpsatolOrion
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Biperiden hydrochloride
Thumb
  • InChI Key: RDNLAULGBSQZMP-UHFFFAOYNA-N
  • Monoisotopic Mass: 347.201592294
  • Average Mass: 347.922
DBSALT000804
Biperiden lactate
ThumbNot applicableDBSALT001327
Categories
UNII0FRP6G56LD
CAS number514-65-8
WeightAverage: 311.4611
Monoisotopic: 311.224914555
Chemical FormulaC21H29NO
InChI KeyInChIKey=YSXKPIUOCJLQIE-UHFFFAOYSA-N
InChI
InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2
IUPAC Name
1-{bicyclo[2.2.1]hept-5-en-2-yl}-1-phenyl-3-(piperidin-1-yl)propan-1-ol
SMILES
OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Aralkylamine
  • Piperidine
  • Tertiary alcohol
  • 1,3-aminoalcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy.
PharmacodynamicsBiperiden is a weak peripheral anticholinergic agent. It has, therefore, some antisecretory, antispasmodic and mydriatic effects. In addition, biperiden possesses nicotinolytic activity. The parenteral form of biperiden is an effective and reliable agent for the treatment of acute episodes of extrapyramidal disturbances sometimes seen during treatment with neuroleptic agents. Akathisia, akinesia, dyskinetic tremors, rigor, oculogyric crisis, spasmodic torticollis, and profuse sweating are markedly reduced or eliminated. With parenteral biperiden, these drug-induced disturbances are rapidly brought under control.
Mechanism of actionParkinsonism is thought to result from an imbalance between the excitatory (cholinergic) and inhibitory (dopaminergic) systems in the corpus striatum. The mechanism of action of centrally active anticholinergic drugs such as biperiden is considered to relate to competitive antagonism of acetylcholine at cholinergic receptors in the corpus striatum, which then restores the balance.
Related Articles
Absorption87% bioavailability
Volume of distributionNot Available
Protein binding60%
Metabolism

The metabolism of biperiden is not completely understood, but does involve hydroxylation.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityLD50=760 mg/kg (Orally in rats). Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9669
Blood Brain Barrier+0.9808
Caco-2 permeable+0.6422
P-glycoprotein substrateSubstrate0.7189
P-glycoprotein inhibitor IInhibitor0.6211
P-glycoprotein inhibitor IINon-inhibitor0.8284
Renal organic cation transporterInhibitor0.7592
CYP450 2C9 substrateNon-substrate0.8119
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5193
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9084
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9056
CYP450 3A4 inhibitorNon-inhibitor0.9041
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9558
Ames testNon AMES toxic0.8194
CarcinogenicityNon-carcinogens0.9309
BiodegradationNot ready biodegradable0.8756
Rat acute toxicity2.6495 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6982
hERG inhibition (predictor II)Non-inhibitor0.6332
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
Tabletoral2 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point114 °CPhysProp
water solubility25.1 mg/LNot Available
logP4.25SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.00426 mg/mLALOGPS
logP4.28ALOGPS
logP3.54ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)13.82ChemAxon
pKa (Strongest Basic)9.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity97.02 m3·mol-1ChemAxon
Polarizability36.74 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.72 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-9000000000-92eb93b999cf7f5ec519View in MoNA
References
Synthesis Reference

Peter Klein, “Method for the production of biperiden II.” U.S. Patent US20040152899, issued August 05, 2004.

US20040152899
General References
  1. Nishiyama K, Mizuno T, Sakuta M, Kurisaki H: Chronic dementia in Parkinson's disease treated by anticholinergic agents. Neuropsychological and neuroradiological examination. Adv Neurol. 1993;60:479-83. [PubMed:8420174 ]
External Links
ATC CodesN04AA02
AHFS Codes
  • 12:08.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Biperiden can be decreased when used in combination with 1,10-Phenanthroline.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Biperiden.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Biperiden.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Biperiden.
AclidiniumAclidinium may increase the anticholinergic activities of Biperiden.
AclidiniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Aclidinium.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Biperiden.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Biperiden.
AlfentanilThe risk or severity of adverse effects can be increased when Biperiden is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Biperiden.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Biperiden is combined with Alphacetylmethadol.
AmbenoniumThe therapeutic efficacy of Biperiden can be decreased when used in combination with Ambenonium.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Biperiden.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Biperiden.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Biperiden.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Biperiden.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Biperiden.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Biperiden.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Biperiden.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Biperiden.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Biperiden.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Biperiden.
BenactyzineThe risk or severity of adverse effects can be increased when Biperiden is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Biperiden.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Biperiden.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Biperiden.
BezitramideThe risk or severity of adverse effects can be increased when Biperiden is combined with Bezitramide.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Biperiden.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Biperiden.
Botulinum Toxin Type ABiperiden may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BBiperiden may increase the anticholinergic activities of Botulinum Toxin Type B.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Biperiden.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Biperiden.
BuprenorphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Biperiden is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Biperiden.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Biperiden.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Biperiden.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Biperiden.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Biperiden.
CarfentanilThe risk or severity of adverse effects can be increased when Biperiden is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Biperiden.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Biperiden.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Biperiden.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Biperiden.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Biperiden is combined with Chlorphenoxamine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Biperiden.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Biperiden.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Biperiden.
CimetropiumBiperiden may increase the anticholinergic activities of Cimetropium.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Biperiden.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Biperiden.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Biperiden.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Biperiden.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Biperiden.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Biperiden.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Biperiden.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Biperiden.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Biperiden.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Biperiden.
CodeineThe risk or severity of adverse effects can be increased when Biperiden is combined with Codeine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Biperiden.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Biperiden.
CoumaphosThe therapeutic efficacy of Biperiden can be decreased when used in combination with Coumaphos.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Biperiden.
CyclopentolateThe risk or severity of adverse effects can be increased when Biperiden is combined with Cyclopentolate.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Biperiden.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Biperiden.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Biperiden.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Biperiden.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Biperiden.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Biperiden.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Biperiden.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Biperiden.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Biperiden.
DecamethoniumThe therapeutic efficacy of Biperiden can be decreased when used in combination with Decamethonium.
DemecariumThe therapeutic efficacy of Biperiden can be decreased when used in combination with Demecarium.
DesloratadineThe risk or severity of adverse effects can be increased when Biperiden is combined with Desloratadine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Biperiden.
DexetimideThe risk or severity of adverse effects can be increased when Biperiden is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Biperiden is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Biperiden is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Biperiden is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Biperiden.
DichlorvosThe therapeutic efficacy of Biperiden can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Biperiden.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Biperiden.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Biperiden.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Biperiden.
DihydrocodeineThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Biperiden.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Biperiden.
DiphenoxylateThe risk or severity of adverse effects can be increased when Biperiden is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Biperiden.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Biperiden.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Biperiden.
DonepezilThe therapeutic efficacy of Biperiden can be decreased when used in combination with Donepezil.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Biperiden.
DPDPEThe risk or severity of adverse effects can be increased when Biperiden is combined with DPDPE.
DronabinolBiperiden may increase the tachycardic activities of Dronabinol.
EchothiophateThe therapeutic efficacy of Biperiden can be decreased when used in combination with Echothiophate.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Biperiden.
EdrophoniumThe therapeutic efficacy of Biperiden can be decreased when used in combination with Edrophonium.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Biperiden.
EluxadolineBiperiden may increase the constipating activities of Eluxadoline.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Biperiden.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Biperiden.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Biperiden.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Biperiden.
EstriolThe serum concentration of Estriol can be increased when it is combined with Biperiden.
EstroneThe serum concentration of Estrone can be increased when it is combined with Biperiden.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Biperiden.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Biperiden.
EthylmorphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Ethylmorphine.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Biperiden.
EtorphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Etorphine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Biperiden.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Biperiden.
FentanylThe risk or severity of adverse effects can be increased when Biperiden is combined with Fentanyl.
FenthionThe therapeutic efficacy of Biperiden can be decreased when used in combination with Fenthion.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Biperiden.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Biperiden.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Biperiden.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Biperiden.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Biperiden.
GalantamineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Biperiden.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Biperiden.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Biperiden.
Ginkgo bilobaThe therapeutic efficacy of Biperiden can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Biperiden is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Biperiden.
GlycopyrroniumBiperiden may increase the anticholinergic activities of Glycopyrronium.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Biperiden.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Biperiden.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Biperiden.
HeroinThe risk or severity of adverse effects can be increased when Biperiden is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Biperiden is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Biperiden can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Biperiden.
HydrocodoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Biperiden.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Biperiden.
HydromorphoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Biperiden.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Biperiden.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Biperiden.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Biperiden.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Biperiden.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Biperiden.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Biperiden.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Biperiden.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Biperiden.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Biperiden.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Biperiden.
IsoflurophateThe therapeutic efficacy of Biperiden can be decreased when used in combination with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Biperiden.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Biperiden.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Biperiden.
KetobemidoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Biperiden.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Biperiden.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Biperiden.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Biperiden.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Biperiden.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Biperiden.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Biperiden.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Biperiden.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Biperiden.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Biperiden is combined with Levomethadyl Acetate.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Biperiden.
LevorphanolThe risk or severity of adverse effects can be increased when Biperiden is combined with Levorphanol.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Biperiden.
LofentanilThe risk or severity of adverse effects can be increased when Biperiden is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Biperiden.
LosartanThe serum concentration of Losartan can be increased when it is combined with Biperiden.
MalathionThe therapeutic efficacy of Biperiden can be decreased when used in combination with Malathion.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Biperiden.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Biperiden.
MefloquineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Biperiden is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Biperiden is combined with Methantheline.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Biperiden.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Biperiden.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Biperiden.
MetixeneThe risk or severity of adverse effects can be increased when Biperiden is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Biperiden.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Biperiden.
MianserinMianserin may increase the anticholinergic activities of Biperiden.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Biperiden.
MinaprineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Biperiden is combined with Mirabegron.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Biperiden.
MorphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Biperiden.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Biperiden is combined with N-butylscopolammonium bromide.
NabiloneBiperiden may increase the tachycardic activities of Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Biperiden.
NalbuphineThe risk or severity of adverse effects can be increased when Biperiden is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Biperiden.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Biperiden.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Biperiden.
NeostigmineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Neostigmine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Biperiden.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Biperiden.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Biperiden.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Biperiden.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Biperiden.
NormethadoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Biperiden is combined with NVA237.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Biperiden.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Biperiden.
OpiumThe risk or severity of adverse effects can be increased when Biperiden is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Biperiden is combined with Orphenadrine.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Biperiden.
OxybutyninThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Biperiden.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Biperiden.
PancuroniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Pancuronium.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Biperiden.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Biperiden.
PentazocineThe risk or severity of adverse effects can be increased when Biperiden is combined with Pentazocine.
PentoliniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Pentolinium.
PethidineThe risk or severity of adverse effects can be increased when Biperiden is combined with Pethidine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Biperiden.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Biperiden.
PhysostigmineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Physostigmine.
PipecuroniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Pipecuronium.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Biperiden.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Biperiden.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Biperiden.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Biperiden.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Biperiden.
Potassium ChlorideBiperiden may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Biperiden.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Biperiden.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Biperiden.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Biperiden.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Biperiden.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Biperiden.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Biperiden.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Biperiden.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Biperiden.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Biperiden.
PyridostigmineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Pyridostigmine.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Biperiden.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Biperiden.
QuinidineThe risk or severity of adverse effects can be increased when Biperiden is combined with Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Biperiden.
RamosetronBiperiden may increase the constipating activities of Ramosetron.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Biperiden.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Biperiden.
RemifentanilThe risk or severity of adverse effects can be increased when Biperiden is combined with Remifentanil.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Biperiden.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Biperiden.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Biperiden.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Biperiden.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Biperiden.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Biperiden.
RivastigmineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Rivastigmine.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Biperiden.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Biperiden.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Biperiden.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Biperiden.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Biperiden is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Biperiden.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Biperiden.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Biperiden.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Biperiden.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Biperiden.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Biperiden.
SolifenacinThe risk or severity of adverse effects can be increased when Biperiden is combined with Solifenacin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Biperiden.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Biperiden.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Biperiden.
SufentanilThe risk or severity of adverse effects can be increased when Biperiden is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Biperiden.
TacrineThe therapeutic efficacy of Biperiden can be decreased when used in combination with Tacrine.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Biperiden.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Biperiden.
TapentadolThe risk or severity of adverse effects can be increased when Biperiden is combined with Tapentadol.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Biperiden.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Biperiden.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Biperiden.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Biperiden.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Biperiden.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Biperiden.
TimololThe serum concentration of Timolol can be increased when it is combined with Biperiden.
TiotropiumBiperiden may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Biperiden.
TolterodineThe risk or severity of adverse effects can be increased when Biperiden is combined with Tolterodine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Biperiden.
TopiramateThe risk or severity of adverse effects can be increased when Biperiden is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Biperiden.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Biperiden.
TramadolThe risk or severity of adverse effects can be increased when Biperiden is combined with Tramadol.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Biperiden.
TrichlorfonThe therapeutic efficacy of Biperiden can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Biperiden.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Biperiden.
TrimethaphanThe risk or severity of adverse effects can be increased when Biperiden is combined with Trimethaphan.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Biperiden.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Biperiden.
TubocurarineThe risk or severity of adverse effects can be increased when Biperiden is combined with Tubocurarine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Biperiden.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Biperiden.
UmeclidiniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Umeclidinium.
VecuroniumThe risk or severity of adverse effects can be increased when Biperiden is combined with Vecuronium.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Biperiden.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Biperiden.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Biperiden.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Biperiden.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Biperiden.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Biperiden.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Hosoi R, Kobayashi K, Watanabe Y, Inoue O: Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain. J Neural Transm (Vienna). 1999;106(7-8):583-92. [PubMed:10907719 ]
  4. Pehl C, Wendl B, Kaess H, Pfeiffer A: Effects of two anticholinergic drugs, trospium chloride and biperiden, on motility and evoked potentials of the oesophagus. Aliment Pharmacol Ther. 1998 Oct;12(10):979-84. [PubMed:9798802 ]
  5. Eltze M: Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105. [PubMed:10370904 ]
  6. Eltze M, Galvan M: Involvement of muscarinic M2 and M3, but not of M1 and M4 receptors in vagally stimulated contractions of rabbit bronchus/trachea. Pulm Pharmacol. 1994 Apr;7(2):109-20. [PubMed:8081071 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23